BR112013014302A2 - vacina fortemente inativada e ainda altamente imunogênica e processo de fabricação da mesma - Google Patents

vacina fortemente inativada e ainda altamente imunogênica e processo de fabricação da mesma

Info

Publication number
BR112013014302A2
BR112013014302A2 BR112013014302A BR112013014302A BR112013014302A2 BR 112013014302 A2 BR112013014302 A2 BR 112013014302A2 BR 112013014302 A BR112013014302 A BR 112013014302A BR 112013014302 A BR112013014302 A BR 112013014302A BR 112013014302 A2 BR112013014302 A2 BR 112013014302A2
Authority
BR
Brazil
Prior art keywords
manufacturing process
highly immunogenic
immunogenic vaccine
strongly inactivated
inactivated
Prior art date
Application number
BR112013014302A
Other languages
English (en)
Inventor
Bernard Fanget
Géraldine Grouard-Vogel
Olivier Dhellin
Pierre Vandepapeliére
Original Assignee
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/963,192 external-priority patent/US20120148526A1/en
Priority claimed from EP10194240A external-priority patent/EP2462950A1/en
Application filed by Neovacs filed Critical Neovacs
Publication of BR112013014302A2 publication Critical patent/BR112013014302A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
BR112013014302A 2010-12-08 2011-12-08 vacina fortemente inativada e ainda altamente imunogênica e processo de fabricação da mesma BR112013014302A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/963,192 US20120148526A1 (en) 2010-12-08 2010-12-08 Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP10194240A EP2462950A1 (en) 2010-12-08 2010-12-08 Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
EP11185320 2011-10-14
PCT/EP2011/072244 WO2012076668A1 (en) 2010-12-08 2011-12-08 Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof

Publications (1)

Publication Number Publication Date
BR112013014302A2 true BR112013014302A2 (pt) 2016-09-20

Family

ID=45346464

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013014302A BR112013014302A2 (pt) 2010-12-08 2011-12-08 vacina fortemente inativada e ainda altamente imunogênica e processo de fabricação da mesma

Country Status (10)

Country Link
US (1) US20130259892A1 (pt)
EP (1) EP2648746A1 (pt)
JP (1) JP2014500267A (pt)
CN (1) CN103347536A (pt)
AU (1) AU2011340477A1 (pt)
BR (1) BR112013014302A2 (pt)
CA (1) CA2820837A1 (pt)
MX (1) MX2013006501A (pt)
RU (1) RU2013125147A (pt)
WO (1) WO2012076668A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3775783D1 (de) 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
FR2677654B1 (fr) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
US5393891A (en) * 1993-06-08 1995-02-28 The Du Pont Merck Pharmaceutical Company Immunoassay reagents and methods for detecting brequinar and analogs
DK0975668T3 (da) 1997-04-15 2006-09-25 Pharmexa As Modificerede TNFa-molekyler, DNA, der koder for sådanne modificerede TNFa-molekyler og vacciner omfattende sådanne modificerede TNFa-molekyler og DNA
FR2812813B1 (fr) 2000-08-09 2004-11-26 Neovacs Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires
FR2844514B1 (fr) 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
ES2382229T3 (es) * 2005-05-24 2012-06-06 Neovacs Procedimiento para la preparación de un producto inmunógeno estable que comprende heterocomplejos antigénicos de FNT alfa y una proteina transportadora

Also Published As

Publication number Publication date
EP2648746A1 (en) 2013-10-16
AU2011340477A1 (en) 2013-06-20
US20130259892A1 (en) 2013-10-03
WO2012076668A1 (en) 2012-06-14
MX2013006501A (es) 2014-02-28
RU2013125147A (ru) 2015-01-20
JP2014500267A (ja) 2014-01-09
CN103347536A (zh) 2013-10-09
CA2820837A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
IL262123A (en) Influenza virus vaccines and their uses
BRPI1014494A2 (pt) vacina pneumocócica e usos da mesma
DK3170508T3 (da) Vaccineformuleringer
HK1199211A1 (en) Influenza virus vaccines and uses thereof
BR112013011856A2 (pt) sistema de implante dental e processo para a fabricação de um sistema de implante dental
BR112014009807A2 (pt) método e montagem de conector médico de retenção de esterilidade
BR112013032635A2 (pt) fibra ótica multimodal e sistema de incorporação da mesma
EP2552479A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
BR112014010658A2 (pt) antígenos e vacinas direcionadas contra enterovírus humano
BR112012029028A2 (pt) laringoscópio, braços de laringoscópio e métodos de fabricação
BR112014012880A2 (pt) tratamento imunogênico do câncer
CO6811814A2 (es) Vacuna de virus dengue inactivado
BR112015004370A2 (pt) composição esterilizada, processo de fabricação da mesma, utilização da mesma, e, kit
DK2547770T3 (da) Levende svækket kimær porcint circovirusvaccine
BRPI1008561A2 (pt) vacinas vivas atenuadas
BR112013012563A2 (pt) bactéria recombinante e processo de elaboração de glicerol
BR112013007486A2 (pt) vacinas de herpesvírus vetorizadas com vírus da doença de newcastle
SMT201700046B (it) Micobatterio ricombinante come vaccino
BR112014005756A2 (pt) vacina
BR112013001514A2 (pt) vacina para influenza
HK1206986A1 (en) Prophylactic/therapeutic agent for influenza virus infection
DK2469159T3 (da) Dental behandlingslysgiver
FR2963241B1 (fr) Vaccin contre le paludisme gestationnel
BR112013029514A2 (pt) composição imunogênica, vacina, e, método de tratar ou impedir uma doença
DK2609931T3 (da) Immunogen sammensætning

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/525 (2006.01), A61K 39/00 (2006.01), A61K

B350 Update of information on the portal [chapter 15.35 patent gazette]